Samsung Bioepis Co. Ltd. 's Ontruzant, a biosimilar version of Roche 's Herceptin (trastuzumab), has become the first trastuzumab biosimilar to get the green light from the European Commission, beating rival products also going through the regulatory approval process in Europe.
Celltrion Inc. also has a biosimilar trastuzumab, Herzuma, under review in the EU, and could be the next to secure a positive opinion the European Medicines Agency, having submitted its dossier at the same time as Samsung Bioepis. Other companies developing biosimilar versions include Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?